Allogene Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

ALLO$1.06+1.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total Stockholders’ Equity
Shares · Amount
Balance - December 31, 2025	229,413,523	$229		$2,302,753		$(2,010,709)		$269		$292,542
Issuance of common stock upon exercise of stock options and vesting of RSUs	2,476,547	2		2		—		—		4
Issuance of common stock from ATM offering, net of commissions and offering costs of $0.3 million	12,476,533	13		20,655		—		—		20,668
Stock-based compensation	—		8,270		—		—		8,270
Employee stock purchase plan	449,810	1		449		—		—		450
Net loss	—	—		—		(42,607)		—		(42,607)
Net unrealized loss on available-for-sale investments	—	—		—		—		(452)		(452)
Balance - March 31, 2026	244,816,413	245		2,332,129		(2,053,316)		(183)		278,875
Issuance of common stock upon vesting of RSUs	329,014	—		—		—		—		—
Issuance of common stock from public offering, net of commissions and offering costs of $12.5 million	100,200,000	100		187,772		—		—		187,872
Stock-based compensation	—	—		12,440		—		—		12,440
Net loss	—	—		—		(42,677)		—		(42,677)
Net unrealized loss on available-for-sale investments	—	—		—		—		(335)		(335)
Balance - June 30, 2026	345,345,427	$345		$2,532,341		$(2,095,993)		$(518)		$436,175

Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity
Shares · Amount
Balance - December 31, 2024	212,210,597	$212	$2,241,879	$(1,819,823)	$(89)		$422,179
Issuance of common stock upon vesting of RSUs	2,158,522	2	(2)	—	—		—
Issuance of common stock from ATM offering, net of commissions and offering costs of $0.2 million	3,842,282	4	9,998	—	—		10,002
Stock-based compensation	—	—	12,175	—	—		12,175
Employee stock purchase plan	386,861	1	637	—	—		638
Net loss	—	—	—	(59,733)	—		(59,733)
Net unrealized gain on available-for-sale investments	—	—	—	—	132		132
Balance - March 31, 2025	218,598,262	219	2,264,687	(1,879,556)	43		385,393
Issuance of common stock upon vesting of RSUs	398,743	—	—	—	—		—
Issuance of common stock from ATM offering, net of commissions and offering costs of $0.02 million	1,136,871	1	1,513			1,514
Stock-based compensation	—	—	8,685	—	—		8,685
Net loss	—	—	—	(50,943)	—		(50,943)
Net unrealized loss on available-for-sale investments	—	—	—	—	(88)		(88)
Balance - June 30, 2025	220,133,876	$220	$2,274,885	$(1,930,499)	$(45)		$344,561

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.